Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese Biotechs Join COVID-19 Treatment Race With Repurposed Cancer Drugs

Executive Summary

Chinese bioventures leap into the COVID cure fray as two little-known companies kick off clinical studies of androgen receptor antagonists in Brazil and the US.

You may also be interested in...



Asia Deal Watch: Hansoh Teams Up With OliX On SIRNA Therapies

Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.

Coronavirus Update: Brii Files US EUA For Antibody Combo

Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral. 

Transcenta Among Chinese Biotechs Raising Funds Through Public Offerings, Private Financings

A combined $447.2m are raised through a Hong Kong initial public offering (IPO) and venture capital and private equity deals.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144916

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel